Fe-Cr-Nb-B ferromagnetic particles with shape anisotropy for cancer cell destruction by magneto-mechanical actuation
Chiriac H., Radu E., Țibu M., Stoian G., Ababei G., Lăbușcă L.
Laboratory Study, published in Sci Rep (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Sci Rep (2018)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 30069055
- PMCID
- PMC6070495
- DOI
- 10.1038/s41598-018-30034-3
- Citations
- 11
Abstract (original English)
We introduce a new type of magnetic particles (MPs) prepared by wet milling of superferromagnetic Fe-Cr-Nb-B precursor glassy ribbons for cancer treatment by magneto-mechanical actuation in low magnetic fields (1 ÷ 20 Oe). The rectangular shapes of MPs and the superferromagnetism of the glassy alloys of which are made the MPs induce important magnetic shape anisotropies which, in association with a large saturation magnetization, generate an improved torque in a rotating magnetic field, producing important damages on the cellular viability of MG-63 human osteosarcoma (HOS) cells. The specific parameters such as MPs concentration, frequency and intensity of the applied magnetic field, or the time of exposure have a strong influence on the cancer cells viability. The specific behavior of the Fe-Cr-Nb-B MPs offers them destructive effect even in low magnetic fields such as 10 Oe, and this characteristic allows the use of coils systems which provide large experimental spaces. The novel MPs are used for the magneto-mechanical actuation alone or in association with hyperthermia, but also can be transported to the tumor sites by means of stem cells carriers.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.